Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

702 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-05-31

Study Completion Date

2014-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aim of the BETAPATH study is to evaluate whether the use of a personal digital assistant (PDA) can improve the adherence of Multiple Sclerosis patients to a therapy with Betaseron. The Personal digital assistant PDA functions as an electronic diary and as an injection reminder.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study

NCT03134573

Multiple Sclerosis

COMPLETED

Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon

NCT02486640

Multiple Sclerosis

COMPLETED

Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron

NCT00461396

Multiple Sclerosis Multiple Sclerosis, Relapsing-Remitting

COMPLETED

PROmyBETAappGame: a Study to Learn More About the Medication Usage & Patient Reported Outcomes Via the myBETAapp and to Find Out More About the Usage of Game Principles and Game Design Elements (Gamification) in Medical Care of Patients With Multiple Sclerosis Treated With Betaferon

NCT03808142

Multiple Sclerosis

COMPLETED

BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program

NCT01233245

Relapsing Remitting MS (RRMS) Secondary Progressive MS (SPMS)

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Relapsing-Remitting Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Interferon beta-1b (Betaseron, BAY86-5046)

Intervention Type DRUG

Interferon beta-1b (Betaferon) and Personal Digital Assistant together with a reminder

Group 2

Interferon beta-1b (Betaseron, BAY86-5046)

Intervention Type DRUG

Interferon beta-1b (Betaferon) and Personal Digital Assistant without a reminder

Group 3

Interferon beta-1b (Betaseron, BAY86-5046)

Intervention Type DRUG

Interferon beta-1b (Betaferon)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Interferon beta-1b (Betaseron, BAY86-5046)

Interferon beta-1b (Betaferon) and Personal Digital Assistant together with a reminder

Intervention Type DRUG

Interferon beta-1b (Betaseron, BAY86-5046)

Interferon beta-1b (Betaferon) and Personal Digital Assistant without a reminder

Intervention Type DRUG

Interferon beta-1b (Betaseron, BAY86-5046)

Interferon beta-1b (Betaferon)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Outpatients with the diagnosis of Multiple Sclerosis and decision by the investigator to prescribe Betaferon.The decision for treatment type and duration is taken before offering the patient the possibility to participate in the study.